Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma
anlotinib was added to TP inductive chemotherapy and definitive chemoradiation in nasopharyngeal carcinoma patients with N2-3 disease with necrosis or/and ECM
Nasopharyngeal Carcinoma
DRUG: Anlotinib hydrochloride|DRUG: induction chemotherapy|RADIATION: concurrent chemoradiation
ORR, tumor objective response rate, induction phase ; 3 months after chemoradiation
PFS, progression-free survival, 3year|LRR, local relapse rate, 3 years|RRR, regional relapse rate, 3 years
anlotinib was added to TP inductive chemotherapy and definitive chemoradiation in nasopharyngeal carcinoma patients with N2-3 disease with necrosis or/and ECM